AB-FUBINACA

From Wikipedia, the free encyclopedia
Jump to: navigation, search
AB-FUBINACA
AB-FUBINACA structure.png
Systematic (IUPAC) name
N-[(1S)-1-(Aminocarbonyl)-2-methylpropyl]-1-[(4-fluorophenyl)methyl]-1H-indazole-3-carboxamide
Clinical data
Legal status Schedule I
Identifiers
CAS number 1185282-01-2 YesY
ATC code ?
PubChem CID 58124325
Chemical data
Formula C20H21FN4O2 
Mol. mass 368.16 g/mol

AB-FUBINACA is a drug that acts as a potent agonist for the cannabinoid receptors, with Ki values of 0.9nM at CB1 and 23.2nM at CB2. It was originally developed by Pfizer in 2009 as an analgesic medication,[1] but was never pursued for human use. Subsequently in 2012, this compound was discovered as an ingredient in synthetic cannabis blends in Japan,[2] along with a related compound AB-PINACA which had not previously been reported.

In January 2014, AB-FUBINACA was designated as a Schedule I controlled substance in the United States.[3]

See also[edit]

References[edit]

  1. ^ Buchler IP et al, INDAZOLE DERIVATIVES. WO 2009/106982
  2. ^ Uchiyama, N.; Matsuda, S.; Wakana, D.; Kikura-Hanajiri, R.; Goda, Y. (2012). "New cannabimimetic indazole derivatives, N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (AB-PINACA) and N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (AB-FUBINACA) identified as designer drugs in illegal products". Forensic Toxicology 31: 93. doi:10.1007/s11419-012-0171-4.  edit
  3. ^ PMID 24876364 (PubMed)
    Citation will be completed automatically in a few minutes. Jump the queue or expand by hand